Abstract 566P
Background
The incidence of lower gastrointestinal tract (GI) cancers among adolescents and young adults (AYAs) is rising. A cancer diagnosis and treatment(s) can lead to long-term morbidity and disrupt physical, cognitive, and psychosocial development, which can result in a reduced health-related quality of life (HRQOL) in this young population. The aim of this study was to describe the long-term survivorship outcomes of AYA with lower GI cancer.
Methods
The Netherlands Cancer Registry identified AYA cancer survivors (aged 18-39 years at initial cancer diagnosis, 5-20 years past diagnosis). They were invited to participate in a population-based, cross-sectional questionnaire study (SURVAYA). Survivorship issues (EORTC QLQ-SURV111) and HRQOL (EORTC QLQ-C30) were assessed. For this secondary analysis, we used data of all participating AYA colorectal and anal cancer patients.
Results
82 SURVAYA participants were selected (43% colon, 47% rectal and 8% anal cancer; 59% male sex; mean age 34 years at study participation; 11.3 years after diagnosis). Primary treatment consisted of surgery (18%); surgery and chemotherapy (23%); surgery and radiotherapy (10%); radiotherapy and chemotherapy (10%); surgery, radiotherapy and chemotherapy (39%); 35% of patients had a stoma. AYA cancer survivors reported to some extent issues related to body image (41%), sexual intimacy (41%), fertility (49%), social isolation (43%), uncertainty about future (71%), reduced career opportunities (55%), reduced income (41%), and getting a mortgage/insurance (49%). Compared to the normative population, AYA cancer survivors experienced higher levels of fatigue (31.9 vs. 19.4), pain (15.4 vs. 11.4), insomnia (22.4 vs 17.3) and diarrhea (16.2 vs. 5.5); and reported lower physical (89.7 vs. 94.8), role (81.1 vs. 91.7), emotional (77.7 vs. 85.4), cognitive (80.0 vs. 92.0) and social functioning (85.3 vs. 93.6). Overall HRQOL was lower for AYAs compared to the norm (72.1 vs. 75.9; all p<0.05).
Conclusions
A substantial proportion of AYA lower GI cancer survivors reports long-term psychosocial and physical survivorship issues. Access to tailored age-specific healthcare resources is needed to maximize their HRQOL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Netherlands Cancer Institute.
Funding
Netherlands Organization for Scientific Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - Progression risk after pregnancy in patients with glioma
Presenter: Annette Leibetseder
Session: Poster session 10
529P - Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Presenter: Wenyin Shi
Session: Poster session 10
530P - Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Presenter: P ANURADHA
Session: Poster session 10
531P - Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users
Presenter: Eleni T. Batzianouli
Session: Poster session 10
532P - Nitric oxide is a target by a combo-drug for glioblastoma treatment
Presenter: Manish Tripathi
Session: Poster session 10
533P - Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 10
534P - Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Presenter: Teresa Pacheco
Session: Poster session 10
535P - Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Presenter: Carla Martín Abreu
Session: Poster session 10
536P - Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Presenter: Niccolò Bertini
Session: Poster session 10
537P - S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Presenter: Ariane Steindl
Session: Poster session 10